News

Molecular Partners Reports Corporate Highlights from Q4 2020 and Key Financials for FY2020

News 05.02.2021 Research & Development Highlights: Virology: Initiated and rapidly advanced COVID-19 antiviral program into the clinic; secured collaboration with Novartis for co-development of multi-specific candidates MP0420 (ensovibep) and MP0423, including options for global commercialization; terms included potential total cash consideration of CHF 215 million, comprised of an upfront payment, equity purchase, and...

read more

Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro

News 04.02.2021 Zurich-Schlieren, Switzerland, February 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced results from a study conducted at Spiez Laboratory. The study assessed leading SARS-CoV-2 anti-infective molecules, including...

read more

Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics

News 14.01.2021 Beijing, CN, Henan, CN and Zurich-Schlieren, CH, January 14, 2021. Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix® prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics. The leading...

read more

Results published of PROPOSe, a real-life prospective study of Proclarix, a novel blood-based test to support challenging biopsy decision making in prostate cancer

News 07.01.2021 Zurich-Schlieren, Switzerland, January 07, 2021 - Proteomedix, the Swiss cancer diagnostics company, announced today that the results of PROPOSe, a prospective multicenter study of Proclarix® in clinical routine use, were published in European Urology Oncology1). Prostate specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or...

read more

Collagen Matrix Acquires the GUIDOR® Synthetic Bone Graft & Membrane Business from Sunstar

News 04.01.2021 OAKLAND, N.J., Dec. 29, 2020 /PRNewswire/ -- Collagen Matrix, Inc., a global leader in regenerative, collagen-based, xenograft-derived medical devices, and portfolio company of Linden Capital Partners ("Linden"), announced today the acquisition of Sunstar's Degradable Solutions division (the "Company"), including its GUIDOR® branded line of resorbable synthetic medical implants. Founded in 1999, Degradable Solutions AG, is...

read more